This white paper presents a prospective clinical study evaluating S-Shearwave Imaging™, Samsung Medison’s advanced ultrasound elastography technology, for improving prostate cancer diagnosis. The study assessed the diagnostic performance of 2D-Shear Wave Elastography (2D-SWE) using the RS85 Prestige system in 38 men with elevated PSA levels and/or suspicious MRI findings.
Using transrectal ultrasound (TRUS), S-Shearwave Imaging™ was applied to evaluate tissue stiffness across 12 prostate sectors. Quantitative elasticity metrics—including maximum (Emax), mean (Emean), and minimum (Emin) Young’s modulus values—were analyzed against biopsy-confirmed results. The study found that stiffness values were significantly higher in cancer-positive regions compared to benign tissues across both patient-based and region-based analyses.
In patient-based analysis, Emean demonstrated the highest diagnostic performance (AUC: 0.840), with 100% specificity and 70.6% sensitivity at a 41.3 kPa cutoff. For predicting clinically significant cancer (CSC), Emax showed the best AUC (0.865), with 84.6% sensitivity and 92.0% specificity at a 52.4 kPa cutoff. Region-based results confirmed SWE’s effectiveness in differentiating benign from malignant tissue, with moderate-to-good interobserver reliability.
S-Shearwave Imaging™ also proved valuable in guiding targeted prostate biopsies, especially when MRI and ultrasound findings were misaligned or unclear. Its real-time stiffness data improves localization accuracy during prostate cancer evaluation and supports clinical decision-making.
For step-by-step clinical use, visit the S-Shearwave Imaging™ Workflow Guide with RS85 Prestige .
